Sarepta Therapeutics, Inc. (SRPT)
17.40
-0.56
(-3.12%)
USD |
NASDAQ |
Feb 12, 16:00
17.45
+0.05
(+0.29%)
After-Hours: 06:16
Sarepta Therapeutics Cash from Investing (Quarterly) : 232.40M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -23.74M |
| Merck & Co., Inc. | -- |
| Pfizer Inc. | -- |
| Keros Therapeutics, Inc. | -0.132M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.37M |
| Cash from Financing (Quarterly) | -105.00M |
| Free Cash Flow | -401.63M |
| Free Cash Flow Per Share (Quarterly) | -0.5549 |
| Free Cash Flow to Equity (Quarterly) | 48.07M |
| Free Cash Flow to Firm (Quarterly) | -48.60M |
| Free Cash Flow Yield | -22.37% |